Plasma dehydroepiandrosterone sulfate levels in patients with major depressive disorder correlate with remission during treatment with antidepressants

Morita, Tokiko; Senzaki, Koji; Ishihara, Ryoko; Umeda, Kazunori; Iwata, Nakao; Nagai, Taku; Hida, Hirotake; Nabeshima, Toshitaka; Yukawa, Kazunori; Ozaki, Norio; Noda, Yukihiro

doi:10.1002/hup.2400

Cited by 15 publications

(11 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it may seem inconsistent with cross-sectional studies showing DHEA(S)-differences in remitted compared to depressed MDD-subjects and associations between DHEAS and MDD-symptom severity (Michael et al, 2000). Moreover, previous studies showed associations between DHEA(S)-reductions and remission during antidepressant treatment (Fabian et al, 2001;Hsiao, 2006;Morita et al, 2014;Paslakis et al, 2010;Schule et al, 2009). However, other studies suggested that these associations between DHEA(S) and remission already exist before treatment (Goodyer et al, 2003;Kurita et al, 2013;Markopoulou et al, 2009) or even before MDD-onset (Goodyer et al, 2000).…”

Section: Trait Vs Statementioning

confidence: 89%

“…trait instead of state) [present data and (Girdler et al, 2012)]. On the other hand, DHEA(S) is cross-sectionally associated with MDD-symptom severity (Michael et al, 2000) and successful treatment with antidepressants (Morita et al, 2014;Paslakis et al, 2010;Schule et al, 2009). This seems to be similar to what have been demonstrated for cortisol ; several explanations for these apparent inconsistencies could be thought of.…”

Section: Trait Vs Statementioning

confidence: 92%

See 1 more Smart Citation

DHEAS and cortisol/DHEAS-ratio in recurrent depression: State, or trait predicting 10-year recurrence?

Mocking

Pellikaan

Lok

et al. 2015

Psychoneuroendocrinology

View full text Add to dashboard Cite

Section: Trait Vs Statementioning

confidence: 89%

Section: Trait Vs Statementioning

confidence: 92%

DHEAS and cortisol/DHEAS-ratio in recurrent depression: State, or trait predicting 10-year recurrence?

Mocking

Pellikaan

Lok

et al. 2015

Psychoneuroendocrinology

View full text Add to dashboard Cite

“…Some authors found lower DHEA-S levels in MDD patients than in healthy subjects [22,23], while others reported increased ones in MDD patients with [24,25] or without psychotic symptoms [26]. In addition, some authors reported that DHEA-S is negatively correlated with the severity of depressive symptoms [23].…”

Section: Introductionmentioning

confidence: 99%

“…In addition, some authors reported that DHEA-S is negatively correlated with the severity of depressive symptoms [23]. In contrast, in a further paper, the hormone concentrations were found to be reduced in patients who adequately responded to antidepressant treatment, while they remained altered in nonremitters [25]. …”

Section: Introductionmentioning

confidence: 99%

Sex Steroids and Major Psychoses: Which Role for DHEA-S and Progesterone?

et al. 2016

View full text Add to dashboard Cite

Objective: Endocrine pathways seem to play a role in the etiology of major psychoses. The identification of biomarkers associated with psychotic symptoms in schizophrenia (SKZ) and mood disorders would allow the identification of high-risk subjects for delusions and hallucinations. The aim of this study was to evaluate dehydroepiandrosterone sulfate (DHEA-S) and progesterone plasma levels in drug-free patients with major psychoses and their relation with the diagnosis and history of psychotic symptoms. Methods: Eighty-nine consecutive drug-free male inpatients with SKZ or mood disorders were recruited, and DHEA-S and progesterone plasma levels were measured. The groups, divided according to pathological/normal-range hormone levels, were compared in terms of clinical variables using χ² tests with Bonferroni's corrections or multivariate analyses of variance. The same analyses were performed for groups divided according to the presence/absence of lifetime psychotic symptoms. Binary logistic regression analysis was performed using hormone levels as independent variables and history of lifetime psychotic symptoms as a dependent one. Results: A higher number of patients with abnormal DHEA-S levels was found to have a family history of major depressive disorder (p < 0.05). Higher DHEA-S levels (F = 8.31; p = 0.005) were found in patients with a history of psychotic symptoms. In addition, binary logistic regression confirmed that DHEA-S levels were associated with a higher probability of lifetime psychotic symptoms (p = 0.037). Conclusions: Our results confirm previous data about the role of endocrine factors in the etiology of major psychoses. A high DHEA-S level might be a risk factor for psychotic symptoms. Studies with larger samples are needed to confirm these data.

show abstract

“…Despite such findings with exogenously administered DHEA(S), the role of endogenous DHEA(S) in neuropsychiatric illness in humans and in MDD in particular, remain unclear. Previous findings in depression have found DHEA and/or DHEA-S concentrations to be decreased (Michael et al, 2000; Mocking et al, 2015; Morgan et al, 2010; Zhu et al, 2015), increased (Assies et al, 2004; Kurita et al, 2013; Morita et al, 2014; Takebayashi et al, 1998), or unchanged (Fabian et al, 2001; Kurita et al, 2013; Markopoulou et al, 2009; Mocking et al, 2015; Paslakis et al, 2010; Romeo et al, 1998) (also reviewed in Maninger et al ., 2009) in depression, compared to non-depressed controls. The relationship between endogenous serum DHEA(S) levels and likelihood of antidepressant-associated remission also remain unclear.…”

Section: Introductionmentioning

confidence: 87%

Higher serum DHEA concentrations before and after SSRI treatment are associated with remission of major depression

Hough

Lindqvist

Epel

et al. 2017

Psychoneuroendocrinology

View full text Add to dashboard Cite

Background Dehydroepiandrosterone (DHEA) and its sulfated ester DHEA-sulfate (DHEA-S), (together DHEA[S]), are the most abundant adrenal steroids in humans and are found in blood and the brain, where they function as neurosteroids with direct receptor affinities. Preclinical studies suggest that DHEA(S) has antidepressant/neuroprotective properties, and exogenously administered DHEA has shown antidepressant efficacy in humans. Nonetheless, the role of endogenous DHEA(S) levels in major depressive disorder (MDD) and antidepressant outcomes remains unclear. Methods Morning fasting serum DHEA(S) concentrations were determined in 36 healthy, unmedicated MDD adults with Hamilton Depression (HDRS) ratings ≥17, and 75 healthy controls. MDD participants then completed eight weeks of open-label SSRI treatment before DHEA(S) levels were re-sampled; those with post-treatment HDRS ratings ≤7 were classified as “Remitters.” Pre- and post-treatment DHEA(S) levels of Remitters and Non-remitters were compared, controlling for age, sex, and BMI. Results Pre-treatment HDRS ratings did not differ between Remitters and Non-remitters (p=0.179). Baseline DHEA levels of Remitters were significantly higher than both Non-remitters (p=0.008) and controls (p=0.004); baseline DHEA-S levels of Remitters were also higher than Non-remitters (p=0.040) but did not significantly differ from controls (p=0.096). Non-remitters did not significantly differ from controls. Post-treatment DHEA(S) levels remained higher in Remitters compared to Non-remitters (DHEA: p=0.013; DHEA-S: p=0.040). Conclusions These data suggest that higher circulating DHEA(S) levels (while unmedicated and after eight weeks of SSRI treatment) predict SSRI-associated remission in MDD. This raises the possibility that endogenous DHEA(S) abundance is a physiological adjunct to SSRI efficacy, as suggested by prior preclinical and clinical studies.

show abstract

Plasma dehydroepiandrosterone sulfate levels in patients with major depressive disorder correlate with remission during treatment with antidepressants

Abstract: These findings suggest that plasma DHEA-S levels can be used as a putative indicator of the state of remission in patients with major depressive disorder. Copyright © 2014 John Wiley & Sons, Ltd.

Cited by 15 publications

References 38 publications

DHEAS and cortisol/DHEAS-ratio in recurrent depression: State, or trait predicting 10-year recurrence?

DHEAS and cortisol/DHEAS-ratio in recurrent depression: State, or trait predicting 10-year recurrence?

Sex Steroids and Major Psychoses: Which Role for DHEA-S and Progesterone?

Higher serum DHEA concentrations before and after SSRI treatment are associated with remission of major depression

Contact Info

Product

Resources

About